NCT05985200

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 3032950 in Healthy Male and Female Subjects (Single-blind, Randomised Within Dose Groups, Placebo-controlled Parallel-group Design)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising intravenous doses of BI 3032950 in healthy male subjects and postmenopausal or surgically sterilised female subjects (women not of child bearing potential (WNOCBP)).

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 3032950	BI 3032950
DRUG	Placebo matching BI 3032950	Placebo matching BI 3032950

Timeline

• Start date: 2023-09-15
• Primary completion: 2024-08-19
• Completion: 2024-08-19
• First posted: 2023-08-14
• Last updated: 2024-11-21

Locations

1 site across 1 country: Belgium